Scalper1 News
Valeant Pharmaceuticals beat analysts’ fourth-quarter estimates Thursday, but analysts were more interested in the Canadian firm’s acquisition strategy in its quest to become the next drug giant. Cash EPS rose 76% vs. a year earlier to $2.15 — 9 cents above the consensus of analysts polled by Thomson Reuters. Sales rose 109% to $2.06 billion, in line. For 2013, EPS rose 51% to $6.24, with sales up 66% to $5.8 billion. Valeant (VRX) Scalper1 News
Scalper1 News